Bev bevacizumab, Cet cetuximab. Full size image Fig. 3: Primary tumour location and survival in the RAS wild-type per-protocol population. Left-sided tumours (N = 273): a progression-free survival, b overall survival; right-sided tumours (N = 75): c progression-free survival, d...
First-line treatment with FOLFOXIRI plus bevacizumab (BEV) is highly effective and regarded as one of the standards-of-care for patients with metastatic co... M Miyo,T Kato,T Yoshino,... - 《Bmc Cancer》 被引量: 0发表: 2020年 A phase Ib/II study of onvansertib (PCM-075) in combin...
13,14,15,16]. In a predominantly older patient population, the sequential escalation from FP/bev to an irinotecan-based doublet plus bevacizumab at tumour progression failed to confirm non-inferiority to upfront combination
Patients with previously untreated mCRC were randomized 1:1 to receive either FOLFIRI plus bevacizumab (FOLFIRI + Bev) or mFOLFOX6 plus bevacizumab (mFOLFOX6 + Bev), stratified by institution, adjuvant chemotherapy, and liver-limited disease. The primary end point was non-inferiority of FOLFIRI ...
546PTUMOUR SHRINKAGE AND RESPONSE OUTCOMES DURING SECOND-LINE PANITUMUMAB (PMAB) + FOLFIRI VS FOLFIRI TREATMENT._html_urlhttp://annonc.oxfordjournals.org/content/25/suppl_4/iv186.2.abstractdoi:10.1093/annonc/mdu333.48Peeters, M... M Peeters,TJ Price,A Cervantes,... - 《Annals of Oncology》 ...
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial Article Open access 04 March 2023 Main Current first- and second-line therapies for metastatic colorectal cancer (mCRC) include a vari...
Of those 772 patients with a previous therapy, 56.7 % received bevacizumab (BEV), 15.3% anti-EGFR antibodies (cetuximab and/or panitumumab) and 14.6 % both agents. 42.1% of RAS-wt and 56.7% of RAS-mut patients received AFL in second line setting. Median global health score at baseline ...
KRAS/NRAS AND BRAF MUTATIONS IN THE 20050181 STUDY OF PANITUMUMAB plus FOLFIRI FOR THE 2ND-LINE TREATMENT OF METASTATIC COLORECTAL CANCER: UPDATED ANALYSISAnnals of Oncology